---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-063028"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:00:04.303348+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edgewise announces positive sevasemten data; FDA provides clear path to first Becker therapy

## Summary
- MESA OLE: 99% enrollment (85 participants); NSAA scores improved 0.8 pts over 18 months, diverging from natural history declines.
- FDA Type C: NSAA endorsed for traditional approval; CANYON alone insufficient; GRAND CANYON may serve as single pivotal study.
- GRAND CANYON on track for topline data Q4 2026; highly powered to show NSAA difference vs placebo over 18 months.
- Duchenne Phase 2 LYNX/FOX: 10 mg dose selected for Phase 3; well-tolerated; FOX suggests slower decline in post-gene therapy patients.
- Plans to meet FDA Q4 2025 for Phase 3 Duchenne design; pivotal study initiation expected in 2026.

## SEC filing metadata
- accession: 0001104659-25-063028
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925063028/0001104659-25-063028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925063028/tm2519221d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-063028
- JSON: https://secwatch.observer/filing/0001104659-25-063028.json
- Plain text: https://secwatch.observer/filing/0001104659-25-063028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.